Medical Care for Adults

The National Center for Health Research reviews important new research as soon as it is published. We cut through the hype regarding various medical treatments to let you know what is proven and what is unknown about the risks and benefits of various treatment options. We do not accept funding from the companies that make medical products, so you can trust that our information is based on science, and not biased by financial ties to the treatments we’re evaluating.

To find the information you need, please use our search box to search for exactly what you are looking for or browse through our various topics on the right. →

Some of these articles were written this year and others were not, however, if they are on our website it means the information is up-to-date. We always scrutinize new research and call the researchers to learn even more. Then we translate it into plain language that everyone can understand.

If you’re looking for more detailed information about cancer, please go to our Cancer Prevention and Treatment website.

If you don’t see what you are looking for on any health topic, please contact us and we will try to get the information you need within a few days.

NCHR Comment on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products

NCHR backs FDA’s proposed guidance to collect standardized race/ethnicity data in clinical trials, which is crucial for addressing safety and efficacy disparities. We also urge a new category, mandatory implementation, and improved diversity to ensure accurate representation and meaningful efficacy and safety data

Guest Lecture by Diana Zuckerman for Georgetown University Grad Students

April 10, 2024 Today I will talk about Chemicals and Heavy Metals in Artificial Turf, Playgrounds, and Neighborhood Lawns: Policies vs. Scientific Evidence. I’m Dr. Diana Zuckerman and I’m president of the National Center for Health Research. Our nonprofit research center and think tank is staffed by scientists, medical professionals, and public health experts. We […]

NCHR Written Testimony in Support of HB457 for the Maryland House of Delegates Environment and Transportation Committee

February 16, 2024: NCHR provides written testimony to the Maryland House of Delegates Environment and Transportation Committee to support HB457, which requires transparency regarding all new artificial turf and infill installation, use, reuse, recycling, and disposal. This information would enable communities to make informed decisions about artificial turf that take into account how long it lasts and its impact on the environment.

NCHR Agrees with CDC Draft Recommendation to Remove Liraglutide and Pertuzumab from the National Institute for Occupational Safety and Health Hazardous Drugs in Healthcare Settings List

February 15th, 2024: NCHR supports the CDC recommendation to remove Liraglutide and Pertuzumab drugs from the NIOSH List of Hazardous Drugs in Healthcare Settings. We agree that due to the to the drugs’ low bioavailability and limited risk of occupational exposures these drugs are unlikely to pose a harm to healthcare workers.

NCHR’s Comment on EPA’s Proposed Lead and Copper Rule Improvements (LCRI)

February 2024: In its public comment, NCHR supported EPA’s proposed lead and copper rule improvements (LCRI) and suggested strengthening safeguards such as lowering the action lead level to 5 ppb or less, more attention to schools, daycares, and afterschool facilities, better enforcement, and not replacing lead pipes with PVC or other dangerous pipes.